Captor Therapeutics Sa · GPW:CTX
Captor Therapeutics Sa — Q1 2023 Earnings Presentation
30 slides from Captor Therapeutics Sa's earnings presentation, May 30, 2023
Slide 1: A new dawn in drug discovery
A new dawn in drug discovery Corporate Presentation – Q1 2023 update May 2023
Slide 2: Legal notice
Legal notice This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the “Issuer”) solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral present
Slide 3: Q1 2023 Executive summary
Q1 2023 Executive summary Announcement of the next steps in the Strategy - increase of authorised share capital Target announcements in CT-01, CT-02 and CT-05 CT-01 - additional compelling in-vivo efficacy data in preclinical studies - moving towards the clinic as planned Financial results - almost
Slide 4: Development of projects and molecular targets announcement
DEVELOPMENT OF PROJECTS AND MOLECULAR TARGETS ANNOUNCEMENT 4
Slide 5: Optigrade discovery platform – importance of structure
OptigradeTM discovery platform – importance of structure OptigradeTM – addressing Molecular Glues, Bifunctional Degraders and novel Ubiquitin E3 Ligases • Industry leading capability in protein engineering and structural biology • Unique structure-guided lead optimization paradigm gives high selecti
Slide 6: Fully owned pipeline
Fully owned pipeline Target Indications Modality Discovery Preclinical* IND Filing Phase IA / IB Phase II GSPT1, Hepatocellular carcinoma, NEK7, MG SALL4 Autoimmunity, CNS, NEK7 MG MCL-1 Liquid & solid tumours BID PKCӨ Autoimmunity, Oncology, BID Transplantation, Metabolism New target MG projects Au
Slide 7: CT-01: Multi-target GSPT1, NEK7 & SALL4 degrader
CT-01: Multi-target GSPT1, NEK7 & SALL4 degrader CPT-6281: first-in-class MG degrader of GSPT1, SALL4 & NEK7 Lung cancer 400k patients GSPT1 degradation leads to an Integrated Stress Response and induction of apoptosis in HCC cells SALL4 is expressed foetal liver, silenced in adults, but often re- e
Slide 8: Convincing tumor growth inhibition in HCC PDX models
Convincing tumor growth inhibition in HCC PDX models Tumor Growth Inhibition Tumor regression 111 97 %Δ Inhibition 75 62 10 randomly selected HCC models, CPT-6281 100mg/kg, BID 42 3 animals per vehicle & treatment groups 35 31 22 Efficacy demonstrated in 8/10 models; TGI>50% in 4 models, LI-1 LI-2 L
Slide 9: Clear synergy of CPT-6281 with an approved drug
Clear synergy of CPT-6281 with an approved drug HUH-7 Xenograft Model NUDE_HUH-7 LI1097 HCC PDX 2000 1750 1500 1250 Vehicle 1000 Compound A, 5mg/kg, QD CPT-6281, 30mg/kg, BID 750 CPT-6281 + Compound A 500 250 0 0 2 4 6 8 10 12 14 Day of treatment 9 CT-01 – GSPT1 Business Use Only | Do not use withou
Slide 10: Captor compound is structurally different to the clinical ones
Captor compound is structurally different to the clinical ones Captor’s Captor’s Captor’s Captor’s liberated Liberated prodrug prodrug active drug active drug <0.05 <0.05 <0.05 <0.05 MRT-2359 MRT-2359 CC-90009 CC-90009 „Tails” comparison; Tanimoto comparison; Tanimoto coefficient <0-1>, where 0 mean
Slide 11: CPT-6281 – pro-drug with target tissue activation
CPT-6281 – pro-drug with target tissue activation 11 CT-01 – GSPT1 Business Use Only | Do not use without written consent of Captor Therapeutics Inc. © 2023
Slide 12: Development timeline – CPT-6281
Development timeline – CPT-6281 Initial indication: Expected milestones: hepatocellular carcinoma CTA submission for initiation of clinical trials in Q3 2023 Degradation profile Phase Ia/Ib top-line data to be reported by the end of 2024 Molecular GSPT1, SALL4 + NEK7 Combination study data by end 20
Slide 13: CT-02: Vast market potential for inflammasome modulators
CT-02: Vast market potential for inflammasome modulators Neuroinflammation Allergy (AD, PD, MS, ALS) Asthma >10 M patients Myocardial infarction Diabetic cardiomyopathy Fibrotic Inflammasome Inflammatory Bowel Disease Lupus Caspase 1 nephritis 1.6 M patients Gout Rheumatoid Arthritis Psoriasis >2 M
Slide 14: Therapeutic edge in autoimmunity through NEK7 degradation
Therapeutic edge in autoimmunity through NEK7 degradation Potent Potent degradation degradation of NEK7 IL-1𝛽 IL-1 IL-18 150 200 150 Target amount [%] DC50=2.5 nM ] % [ Dm a x=94% 150 t n 100 100 u o 100 m a t e 50 50 g r 50 a T 0 0 0 T S 0 MM U LP5 N IG S O 9µµ µM 10 -11 10 -10 10 -9 10 -8 10 -7…
Slide 15: Differentiated intervention in NLRP3 pathway via NEK7 degradation
Differentiated intervention in NLRP3 pathway via NEK7 degradation Aberrant activation Disease of NLRP3 development Therapeutic response Increased infections via reduced immunity NEK7 NLRP3 inhibition Complete inactivation of IL-1β NLRP3 Therapeutic response Maintained immunity NLRP3 NEK7 degradation
Slide 16: In vivo PoC in peritonitis model & brain penetration
In vivo PoC in peritonitis model & brain penetration -24h 0h 2h 4h 6h Plasma and brain concentration of CPT-565 Concentration [ng/g] Brain 1000 Single MSU Terminal Plasma dose of induction bleeding & CPT- LPS In-life collection 100 764 challenge bleeding 10 IL-1β levels 1 400 Plasma 4h Plasma 6h Per
Slide 17: NEK7 summary
NEK7 summary Multiple series of NEK7 molecular glue degraders discovered Lead compounds show low nanomolar potency and excellent PK properties Molecular Glue In-vivo proof-of-efficacy for systemic degraders achieved in initial study Larger optimised efficacy study reporting soon Significant brain pe
Slide 18: CT-03: MCL-1 – a critical pathway of cancer resistance
CT-03: MCL-1 – a critical pathway of cancer resistance MCL-1 is one of the most amplified proteins in cancer Lung cancer 400k patients A critical resistance mechanism in haematological and solid tumours Ablation of MCL-1 protein directly attenuates tumours in vivo as monotherapy & sensitizes tumors
Slide 19: MCL-1 degraders effective in AML and lung cancer models
MCL-1 degraders effective in AML and lung cancer models Strong tumor growth inhibition Potent MCL-1 degradation and apoptosis kDa Vehicle CPT-2036 50 37 MCL-1 150 PARP FL 100 PARP CL 75 20 15 CC3 50 Stain Free blot 37 Mice with 150 mm3 MV4-11, IV DMS-114, 75 mpk, IV, single injection 19 CT-03 – MCL1
Slide 20: Ultrapotent compounds active ex vivo and in cancer cell lines
Ultrapotent compounds active ex vivo and in cancer cell lines ABU-098 is more potent than ABS-994 in most of the ] 150 ABU-098 tested models [% ] 150 e 125 c CPD-1 ABU-098 ABU-098 + ABR-183 10 CTG-3950 CTG-4044 % [ n e 125 c a d 100 ABU-098 + ABR-183 DC50 ~1 nM 9 CPD-1 was tested in the panel of 30
Slide 21: Development timeline – CT-03
Development timeline – CT-03 Initial indications: Expected milestones: blood cancers, subsequently solid tumours • IND/CTA approval in Q3/4 2024 Bifunctional Degrader • Initiation of Phase I clinical trial Q4 2024 Degradation profile: • Phase Ia/Ib top-line data reported 2025 Selective first-in-clas
Slide 22: CT-05: PKCθ an inadequately drugged high value target
CT-05: PKCӨ an inadequately drugged high value target Multiple sclerosis TCR Allergy Asthma CD3 CD28 T-cell membrane Cytoplasm Myocarditis Breast cancer PKCθ IL-2 Kidney injury IL-17 Gastrointestinal cancer Nucleus Inflammatory Bowel Disease Psoriasis 1.6 M patients 22 CT-05 – PKCӨ >7 M patients Bus
Slide 23: Unique opportunity tailored for bifunctional degraders
Unique opportunity tailored for bifunctional degraders Multiple PKCӨ inhibitors were in clinical trials: Inhibitor shows significant effects on non-immune cells 1st generation, e.g. pan-PKC Sotrastaurin – many side effects Degrader has no effect in non-immune cells 2nd generation, e.g. Astellas, Abb
Slide 24: Captor Partnering
Captor Partnering Existing collaborations: • Sosei Heptares collaboration was extended and continues as planned • Ono partnership is advancing well with positive data confirming our approach Pipeline partnering strategy: • CT-01 + CT-03: Early clinical trials for human POC and partner at point of op
Slide 25: Financials and plans for the future
FINANCIALS AND PLANS FOR THE FUTURE 25
Slide 26: Strong balance sheet and cash position
Strong balance sheet and cash position Consolidated statement of financial position (PLN, M) Cash position 101,3 96,3 91,7 83,4 Available funding secured (PLN M; as of 31/03/2023): 146,7 Total : - PLN 146,7 M 64,2 82,5 • PLN 82,5 M 16,1 13,4 10,5 11,7 cash, short-term bonds 2,7 3,3 • PLN 64,2 M Fixe
Slide 27: Next steps
Next steps 2023 • CT-01: Phase Ia/Ib initiation in liver cancer patients • CT-02 and CT-05: In vivo proof of concept in autoimmunity • In cell degradation of target with novel E3 ligase-based degrader 2024 • CT-03: Phase Ia/Ib initiation in haematological cancer patients • CT-01: Clinical readouts:
Slide 28: Q&A Session
Poa Captor ° Therapeutics Q&A SESSION Therapeutics
Slide 29: Captor Therapeutics S.A contact details
Captor Therapeutics S.A ul. Duńska 11 54-427 Wrocław, Poland Captor Therapeutics GmbH Hegenheimermattweg 167A 4123 Allschwil, Switzerland Contact: t.shepherd@captortherapeutics.com
Slide 30: Projects are co-financed by the European Regional Development Fund
Projects are co-financed by the European Regional Development Fund: Discovery and development of a new clinical drug candidate for the eradication of cancer stem cell in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor (POIR.01.01.01-00-0740/19-00) Dis